Nafata 360 Pharma International Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 7 Year, 16 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.00 M
- Revenue Growth -36.77%
- Profit Growth -299.23%
- Ebitda 157.08%
- Net Worth -3395.08%
- Total Assets -81.65%
About Nafata 360 Pharma International
Nafata 360 Pharma International Private Limited (N3PIPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 January 2018 (Seven years 16 days old ). Its registered office is in Kollam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹1.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nazarudeen Ebrahimkutty and Fathahudeen serve as directors at the Company.
Company Details
-
Location
Kollam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KL2018PTC051891
-
Company No.
051891
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Jan 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Nafata 360 Pharma International?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nazarudeen Ebrahimkutty
|
Director | 23-Jan-2018 | Current |
|
Fathahudeen
|
Director | 23-Jan-2018 | Current |
Financial Performance of Nafata 360 Pharma International.
Nafata 360 Pharma International Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 36.77% decrease. The company also saw a substantial fall in profitability, with a 299.23% decrease in profit. The company's net worth observed a substantial decline by a decrease of 3395.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nafata 360 Pharma International?
Unlock access to Nafata 360 Pharma International's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0
₹1.00 M
Charges Breakdown by Lending Institutions
- Canara Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Jul 2018 | Canara Bank | ₹1.00 M | Satisfied |
How Many Employees Work at Nafata 360 Pharma International?
Unlock and access historical data on people associated with Nafata 360 Pharma International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nafata 360 Pharma International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nafata 360 Pharma International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.